KaloBios removes Shkreli as CEO
Reuters
December 21, 2015 07:40 MYT
December 21, 2015 07:40 MYT
Shkreli (C) departs the U.S. Federal Court after an arraignment following him being charged in a federal indictment filed in Brooklyn relating to his Management and biopharmaceutical company Retrophin Inc. in New York. - Photo Reuters/Lucas Jackson
Drugmaker KaloBios Pharmaceuticals Inc said it removed Martin Shkreli as chief executive on Dec. 17, the day he was arrested on charges of a securities fraud.
Shkreli, who stepped down as CEO of private drugmaker Turing Pharmaceuticals Inc, also resigned from KaloBios' board of directors.
Shkreli was arrested for engaging in what U.S. prosecutors said was a Ponzi-like scheme at his former hedge fund and a pharmaceutical company he previously headed.
The boyish pharmaceuticals entrepreneur was released on a $5 million bond on Thursday.
Shkreli lost control of his Twitter account to hackers on Sunday, hours after he took to the microblogging service to plead his innocence, said his spokesman, Craig Stevens.
KaloBios, which was planning to wind down, named Shkreli as its CEO on Nov. 20, after Shkreli and a consortium of investors bought about 70 percent of the company's shares.
The drug developer said on Monday that Tony Chase, who was appointed to the company's board along with Shkreli, had also resigned.
Trading in KaloBios shares was halted on Monday for the third straight session.